louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05077020: Somatic Diseases in Autistic Children
Official title: Medical Monitoring and Somatic Diseases in Children Who Suffer From Autism Spectrum Disorder (ASD)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autistic Spectrum Disorder
Somatic Disorders
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-10-13
Enrollment: 27
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children followed by psychiatrists in Montpellier university hospital refered to a somatic pediatrician

Brief summary: For many reasons, medical monitoring in autistic patients is very difficult. This study is designed to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases...) in patients suffering from ASD to prevent them or diagnose them earlier.

Detailed description: Mean goal : to determine the prevalence of comorbid diseases (neurological, cardiac, digestive, dental diseases...) in patients suffering from ASD to prevent them or diagnose them earlier.

Secondary goals :

* to obtain an objective assessment of the "general" monitoring in these patients (vaccinations, growth...)
* to assess their habits (food, sleep, screen exposition)
* to determine, in this monitoring and the habits, vigilance points which will need a specific pediatric consultation.

Eligibility criteria: Inclusion criteria:

- consultation after psychiatric evaluation

Exclusion criteria:

* age \> 18 years
* Impossibility to obtain the consent of parents / legal representatives.

Primary outcomes:
measure: Determine the prevalence of comorbid diseases
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Eric JEZIORSKI
role: STUDY_DIRECTOR
References:
Clinical trial NCT04277520: Postoperative Pain Assessment After Using Different Kinematics
Official title: Postoperative Pain Assessment After Using Different Kinematics During Endodontic Instrumentation (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Root Canal Therapy
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2020-02-20
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate postoperative pain after endodontic instrumentation using rotation, reciprocation and adaptive motion.

Detailed description: Post operative pain assessment is done at the end of the session Visual Analog Scale (VAS) questionnaires were handed out to the patients and they were asked to assign a number correlating to their post-treatment pain, with 0 representing no pain and 10 representing the most severe pain imaginable.These scores were marked in intervals of 6, 12, 24, 48 and 72 h following endodontic treatment.

Eligibility criteria: Inclusion Criteria:

1. Medically free patients with good health.
2. Patient's age between 18_50
3. Mandibular first molars teeth diagnosed clinically and radiographically as acute irreversible pulpitis with no evidence of apical pathosis
4. Positive patient's acceptance for participation in the study

Exclusion Criteria:

* Root resorption
* Non restorable teeth.
* Pregnancy.
* Systematic disease as hypertension ,diabetes .
* Psychologically disturbance.
* Need for prophylactic antibiotics

Primary outcomes:
measure: monitoring the change in postoperative pain following root canal treatment
timeFrame: 72 hours
Secondary outcomes:
measure: 6-hour post operative pain assessment
timeFrame: 6 hours
measure: 12-hour post operative pain assessment
timeFrame: 12 hours
measure: 24-hour post operative pain assessment
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Ainshams University
Study officials:
affiliation: Faculty of Dentistry, Ain Shams university
name: Ahmed Hashem, PhD
role: STUDY_DIRECTOR
References:
citation: Gambarini G, Testarelli L, De Luca M, Milana V, Plotino G, Grande NM, Rubini AG, Al Sudani D, Sannino G. The influence of three different instrumentation techniques on the incidence of postoperative pain after endodontic treatment. Ann Stomatol (Roma). 2013 Mar 20;4(1):152-5. doi: 10.11138/ads.0152. Print 2013 Jan.
Clinical trial NCT00033020: Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1
Official title: Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Substance-Related Disorders
Keywords: substance use disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2002-04-08
Enrollment: 390
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.

Detailed description: The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. The study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

Eligibility criteria: Inclusion Criteria:

1. Recent admission to an opioid substitution (methadone maintenance) CTP. Completed at least 4 weeks of maintenance at time of study entry
2. Evidence of cocaine or methamphetamine use Minimum of one documented positive urine within 2 weeks of study entry. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment

Exclusion Criteria:

1. Unable to give informed consent (fails simple consent quiz)
2. Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous gambling problems?

Primary outcomes:
measure: ASI
measure: Opioid and cocaine use
measure: AIDS risk behavior
Secondary outcomes:
Other outcomes:
Locations:
city: Bakersfield
country: United States
facility: Aegis Medical Systems, Inc.
state: California
city: Washington
country: United States
facility: Oasis Clinic
state: District of Columbia
city: Baltimore
country: United States
facility: Glenwood Life Counseling Center
state: Maryland
city: New York
country: United States
facility: Lower Eastside Service Center (LESC)
state: New York
city: New York
country: United States
facility: Greenwich House, Inc.
state: New York
city: Philadelphia
country: United States
facility: ACT
state: Pennsylvania
city: Charleston
country: United States
facility: Charleston Center
state: South Carolina
Study officials:
affiliation: Johns Hopkins University
name: Maxine Stitzer, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06925620: Effectiveness of a Multimodal IT Enhanced Hand Hygiene Strategy on Healthcare Associated Infections in Nursing Homes
Official title: Effectiveness of Multimodal Information Technology-enhanced Hand Hygiene Improvement Strategy on Healthcare-associated Infections in Nursing Homes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Accuracy
Compliance
Healthcare-associated Infections
Keywords: Accuracy
Compliance
Density of Healthcare-Associated Infections
Information Technology
Knowledge
Multimodal Hand Hygiene Improvement Strategies
Nursing Homes
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2025-04-13
Enrollment: 91
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate the effectiveness of a multimodal hand hygiene improvement strategy, enhanced with information technology (IT), in reducing healthcare-associated infections (HAIs) in nursing homes. The goal is to improve infection prevention practices and promote a safer environment for older adults living in long-term care facilities.

Detailed description: Hand hygiene is a key strategy for preventing healthcare-associated infections (HAIs), yet compliance among healthcare workers remains suboptimal due to knowledge gaps, limited resources, unfamiliarity with procedures, and poor adherence. This study aims to assess the effectiveness of an IT-enhanced multimodal hand hygiene intervention in reducing HAIs within nursing homes, thereby improving infection control practices and promoting a safer environment for older adults in long-term care settings.

Eligibility criteria: Inclusion Criteria:

* Full-time nurses or nursing assistants in the participating nursing homes
* Proficiency in Mandarin or Taiwanese

Exclusion Criteria:

• Confirmed or anticipated resignation

Primary outcomes:
measure: Hand Hygiene Knowledge
timeFrame: 1 month
measure: Hand hygiene Compliance Rates
timeFrame: 4 month
measure: Hand hygiene Accuracy Rates
timeFrame: 4 month
measure: Density of healthcare-associated infections
timeFrame: 4 month
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Nursing Home
city: Pingtung
country: Taiwan
facility: Pingtung Nursing Home
Study officials:
References:
Clinical trial NCT01486420: Open Surgery Versus Corticosteroid Injections in Treatment of Trigger Finger
Official title: Open Surgery Versus Ultrasound Guided Local Corticosteroid Injections in Treatment of Trigger Finger - a Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trigger Finger
Keywords: Quinell grade
Open surgery
corticosteroid injections
randomized controlled trial
Trigger finger
Lead sponsor: Regionshospitalet Silkeborg
Sponsor class: OTHER
First posted: 2011-12-06
Enrollment: 166
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate which strategy is superior in trigger finger Quinell grade IIb-V; conventional open surgery or ultrasound guided corticosteroid injections.


Eligibility criteria: Inclusion Criteria:

* Trigger finger Quinell grade IIb-V in digit I-V

Exclusion Criteria:

* Former treatment of Trigger finger in affected digit
* Dupuytrens contracture in affected digit
* Allergies or intolerance to used medications
* Rheumatoid Arthritis
* Insulin dependent Diabetes Mellitus
* Amyloidosis
* Mucopolysaccharidosis
* Already included in study with another digit

Primary outcomes:
measure: Quinell grade
timeFrame: 12 months
Secondary outcomes:
measure: Numerical Rating Scale (NRS) score
timeFrame: 12 weeks
measure: infection
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Silkeborg
country: Denmark
facility: Center for Planned surgery - Regionalhospital Silkeborg
Study officials:
affiliation: Center for Planned Surgery - Regionalhospital Silkeborg
name: Jeppe Lange, M.D.
role: STUDY_DIRECTOR
References:
citation: Hansen RL, Lange J. Surgery versus ultrasound-guided steroid injections for trigger finger disease: protocol of a randomized controlled trial. Dan Med J. 2013 May;60(5):A4633.
Clinical trial NCT01286220: Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
Official title: A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Moderate to Severe Atopic Dermatitis
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
Collaborators: name: Children's Medical Center Dallas
First posted: 2011-01-31
Enrollment: 27
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if twice weekly 10 minute dilute bleach baths decreases disease severity in patients with moderate to severe atopic dermatitis.


Eligibility criteria: Inclusion Criteria:

* 2-17 years of age at time of consent. A parent or legal guardian will be required to consent and authorize their enrollment in the study.
* Male or female of any ethnic background.
* English or Spanish speaking.
* A clinical diagnosis of atopic dermatitis for at least 6 months prior to enrollment.
* Must have moderate to severe atopic dermatitis as rated by the EASI score.
* Able to adhere to study visit schedule and other protocol requirements.
* Patients and/or family members must agree to not use any other prescription or over the counter medications other than the ones prescribed by the study protocol.

Exclusion Criteria:

* Clinical evidence of bacterial or viral superinfection on first visit.
* Have received phototherapy within 2 months prior to enrollment.
* Have received any systemic medication for atopic dermatitis or any that may affect evaluation of atopic dermatitis within 2 months prior to enrollment.
* Have a known hypersensitivity response, including anaphylaxis, to any of the topicals used for treatment (i.e. topical steroids, bleach)
* Participation in another clinical trial using an investigational agent or procedure.
* Pregnant or planning pregnancy or surgery during the participation in the study.

Primary outcomes:
measure: Eczema Area and Severity Index Score (EASI)
timeFrame: Change in EASI score from baseline at 1 month and 3 month follow ups
Secondary outcomes:
measure: Investigator's Global Assessment (IGA)
timeFrame: Change in IGA score from baseline at 1 month and 3month follow ups
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Children's Medical Center of Dallas
state: Texas
Study officials:
References:
citation: Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May;123(5):e808-14. doi: 10.1542/peds.2008-2217.
Clinical trial NCT05797220: The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure
Official title: Retrospective Analysis on the Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure: Short and Long-term Outcomes From a Single Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anal Fissure Chronic
Keywords: botulinum toxin, anal fissure, diltiazem
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-04-04
Enrollment: 217
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female and males older than 18 years old

Brief summary: Anal fissure (AF) is a painful tear extending from the anal canal to the dentate line. Although the exact pathophysiology is not known, an increase in anal tonus, decreased ano-dermal blood flow and local ischemia are possible mechanisms. The most effective treatment modality in chronic AF is lateral internal sphincterotomy however, incontinence rates are still reported as high as 8-30%. Topical diltiazem and botulinum toxin (BT) injection are good alternatives to surgery with lack of persistent side effects, easy applicability, and reproducibility, however, recurrence rates were reported up to 50% for each. A combination of BT with topical diltiazem may provide better results in terms of healing and recurrence. In this retrospective analysis a comparison of BT injection alone and BT injection combined with topical diltiazem treatment was performed.


Eligibility criteria: Inclusion Criteria:

* Patients with complaints longer than 8 weeks (chronic anal fissure)
* Patients who completed at least 24 months of follow-up (3rd day, 10th day, 1st-month, and 2nd-month face-to-face clinic visits and 6, 12, and 24 months phone calls)
* Patients who received conservative treatments including topical diltiazem and nitrites

Exclusion Criteria:

* Patients with previous anal surgery (lateral internal sphincterotomy, hemorrhoidectomy, anal fistula)
* Patients with inflammatory bowel diseases
* Patients with accompanying anorectal disease (hemorrhoids, anal fistula, abscess)
* Patients who underwent botulinum toxin injection within 1 year before recruitment
* Patients with anterior, lateral, or multiple fissures
* Comorbidities (AIDS, sexually transmitted disease, tuberculosis, leukemia)
* Pregnancy
* Prescription of calcium canal blockers or nitrites
* Hypersensitivity to diltiazem or botulinum toxin
* Patients without anal pain

Primary outcomes:
measure: Fissure healing at 1 month
timeFrame: 1 month
measure: Days to pain-free defecation
timeFrame: 1 month
Secondary outcomes:
measure: Complete healing at 48 months
timeFrame: 48 months
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
state: Other (Non U.s.)
Study officials:
affiliation: Medipol University
name: Naciye Cigdem Arslan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01326520: Effect of Dietary Phospholipids on Atopic Dermatitis
Official title: Effect of Dietary Milk Phospholipids on Subjects With Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermatitis, Atopic
Lead sponsor: University of Jena
Sponsor class: OTHER
First posted: 2011-03-31
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to investigate the influence of a milk phospholipid enriched dairy product on subjects with atopic dermatitis determining parameters of the immune status, the plasma lipid profile and the skin texture.

Detailed description: Based on the facts, that on the one hand milk phospholipids are characterized by a high sphingolipid content and on the other hand a disturbed sphingolipid metabolism in the epidermis of patients with atopic dermatitis was verified, a double blinded, controlled, randomized, cross-over study with a daily supplementation of 3 g milk phospholipids to subjects with a mild to moderate atopic dermatitis will be conducted.

Forty patients will be randomized between two groups of each 20 patients. After an individual checkup and a run-in period of 2 weeks, the one group will receive the phospholipid enriched dairy product and the second group will be given a placebo dairy product over two month. A wash out-period of 4 weeks will follow, and the patients will consume the contrary dairy products over two month after a 2-week run-in period again.

Eligibility criteria: Inclusion Criteria:

* mild to moderate atopic dermatitis (SCORAD \< 30)
* age: 18 - 60 years

Exclusion Criteria:

* intolerance against milk proteins
* systemic medication with corticosteroids or antihistamines
* immune mediated disease
* atherosclerosis
* hyperlipidaemia
* diabetes mellitus
* angina pectoris
* adipositas
* pregnancy and breast feeding

Primary outcomes:
measure: Change in skin texture from baseline and in comparison with placebo
timeFrame: after 0,2,10,16, and 24 weeks
Secondary outcomes:
measure: Immune status
timeFrame: after 0,2,10,16, and 24 weeks
measure: Lipid status
timeFrame: after 0,2,10,16, and 24 weeks
Other outcomes:
Locations:
city: Jena
country: Germany
facility: Friedrich Schiller University Jena, Department of Nutritonional Physiology
state: Thuringia
Study officials:
affiliation: Friedrich Schiller Univesity of Jena, Department of Nutritional Physiology
name: Gerhard Jahreis, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Keller S, Le HY, Rodiger C, Hipler UC, Kertscher R, Malarski A, Hunstock LM, Kiehntopf M, Kaatz M, Norgauer J, Jahreis G. Supplementation of a dairy drink enriched with milk phospholipids in patients with atopic dermatitis - a double-blind, placebo-controlled, randomized, cross-over study. Clin Nutr. 2014 Dec;33(6):1010-6. doi: 10.1016/j.clnu.2014.01.014. Epub 2014 Jan 29.
Clinical trial NCT01165320: A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
Official title: A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Candidiasis, Esophageal
Candidiasis, Invasive
Aspergillosis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2010-07-19
Enrollment: 20
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.


Eligibility criteria: Inclusion Criteria:

* Japanese patients in whom a causative fungus is detected before treatment with the study drug or patients with strongly suspected deep-seated fungal infection due to Candida species (spp.) or Aspergillus spp.

Exclusion Criteria:

* Patients with mycoses other than ones due to Candida spp. or Aspergillus spp.
* Patients who will receive other systemic antifungal agents for the first time in screening period

Primary outcomes:
measure: Percentage of Participants With an Overall Favorable Response to Therapy
timeFrame: Invasive candidiasis: up to 56 days; aspergillosis: up to 84 days
measure: Percentage of Participants With One or More Drug-Related Adverse Experiences
timeFrame: Invasive candidiasis: up to 70 days; aspergillosis: up to 98 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Mori M, Imaizumi M, Ishiwada N, Kaneko T, Goto H, Kato K, Hara J, Kosaka Y, Koike K, Kawamoto H, Maeda N, Yoshinari T, Kishino H, Takahashi K, Kawahara S, Kartsonis NA, Komada Y. Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis. J Infect Chemother. 2015 Jun;21(6):421-6. doi: 10.1016/j.jiac.2015.01.009. Epub 2015 Jan 30.